Navigation Links
Study shows durable viral suppression of boosted REYATAZ in treatment-experienced HIV patients
Date:11/9/2010

(GLASGOW, 9 November 2010) Results from a European Observational Study, which included 1,294 antiretroviral (ARV)-experienced patients presented today at the Tenth International Congress on Drug Therapy in HIV Infection (HIV10), demonstrated a low rate of discontinuation and sustained virologic suppression with REYATAZ (atazanavir)/ritonavir-based regimens over a follow-up period of up to five years.1

The aim of this study was to investigate the long-term outcomes of REYATAZ/ritonavir-containing regimens in ARV-experienced patients in a real-life clinical setting. The primary endpoint of the cohort study was the proportion of patients who remained on treatment over time by baseline HIV-1 RNA level (< 500 copies/mL and >= 500 copies/mL). Secondary endpoints were reasons for discontinuation, time to virologic failure (defined as either two consecutive HIV-1 RNA >= 50 copies/mL or one HIV-1 RNA >= 50 copies/mL followed by discontinuation) and long-term safety profile.1

The results of the study revealed that 56% of patients with baseline viral suppression (< 500 copies/mL) (n= 722) and 53% of those with detectable viral load (>= 500 copies/mL) (n= 540) remained on treatment after 3 years with a median time to discontinuation of 4 versus 3.6 years, respectively. The overall discontinuation rate in the study was low (43%) with the reasons for discontinuation including adverse events (11%), withdrawn consent (6%) and lack of efficacy (6%). After three years on a REYATAZ/r-based regimen, 75% of patients with baseline HIV-1 RNA levels < 50 copies/mL remained suppressed and 51% of patients with baseline HIV-1 RNA levels >=50 copies/mL achieved and maintained virological suppression.1

Long-term safety outcomes from this real-life study were consistent with data observed in clinical trials: diarrhoea (4%), renal and urinary disorders (3%), nausea (< 1%) and jaundice (< 1%) were reported. Discontinuations due to hyperbilirubinemia were infrequent (< 1%) and no new or unexpected adverse events were observed.1

"Prior to this cohort study, less was known about long-term outcomes and the length of time on treatment in experienced patients after switching", said Professor Jan van Lunzen, M.D., Ph.D. of The University Medical Centre Hamburg-Eppendorf in Germany. "This cohort study shows in a real-life setting that a significant proportion of treatment-experienced patients stayed on an atazanavir/ritonavir-containing regimen for up to five years", he added.

Study Design

This real-life long-term cohort was a non-comparative, retrospective, observational study that collected data from three European databases (France DatAids; Germany KompNet; Sweden InfCare). Clinical data from 1,294 ARV-experienced adult patients who started an atazanavir/ritonavir-based regimen between October 2004 and March 2007 were collected every six months (maximum follow-up of five years). Patients were predominately male (74%); their median age was 43 years and 75% had prior exposure to protease inhibitors (PIs).


'/>"/>

Contact: Annie Simond
33-015-883-6566
TogoRun
Source:Eurekalert

Related medicine news :

1. Statins Dont Reduce Colon Cancer Risk, Study Finds
2. Potential drug therapy for diabetic retinopathy under study
3. Study Warns of Risks for Early Dialysis
4. Breast-Feeding Wont Rob Mom of Sleep: Study
5. Dangerous chemicals in food wrappers likely migrating to humans: U of T study
6. Brain bleeding is common with aging, UCI study finds
7. Study sheds light on aromatase inhibitor joint pain syndrome
8. APHA 2010: Study finds funding for substance abuse in Indiana lacking
9. Study: Tai Chi relieves arthritis pain, improves reach, balance, well-being
10. New Malaria Drug Proves Effective in Study of African Children
11. Psychopaths May Lack Understanding of Social Contracts: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... A national ergonomics ... and Expo event March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, ... As the longest running and largest worker's compensation event in Ohio, organizers of ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions - Time: ... Time: 7:00pm – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over steep cost increases ... D a decade ago, according to The Senior Citizens League (TSCL). ... are coping with rapidly rising costs. “The implications are chilling, particularly for people ...
(Date:2/10/2016)... ... February 09, 2016 , ... According to a recent article ... in the number of patients under the age of 30. According to Southern California ... their offices, and may indicate an overall shift in the rapidly growing social acceptance ...
(Date:2/9/2016)... ... February 09, 2016 , ... Center ... who are diagnosed with autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid ... applied behavior analysis (ABA) is key to providing effective treatment for individuals with ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016  Astellas Pharma Inc. (TSE: 4503, President and ... it has successfully completed, through its indirect wholly-owned subsidiary ... all issued and outstanding shares of common stock of ... Paul Wotton , "Ocata") for a price of US$8.50 ... Offer"). Astellas commenced the Tender Offer on November 19, ...
(Date:2/10/2016)... Tenn. , Feb. 10, 2016 /PRNewswire/ ... of Nursing received an in-kind gift ... of a VeinViewer® Vision vein finder for ... will help students as they learn how ... combining technology with traditional technique. ...
(Date:2/10/2016)... MOUNTAIN VIEW, Calif. , Feb. 10, ... result of a synergistic confluence of various ... unique value propositions, previously unavailable. These opportunities ... convergence and convergence, in turn, drives the ... Today,s entrepreneurial scenario is characterized by technology ...
Breaking Medicine Technology: